Impact of organism species on microbial eradication and development of resistance in severe gram-negative pneumonia

Journal of Chemotherapy

Volumn 22, Issue 2, 2010, Pages 103-109

  Kiem, S ^a   Schentag, Jerome J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Gram negative bacteria; Pharmacodynamics; Pneumonia

Indexed keywords

CEFMENOXIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; PIPERACILLIN; TOBRAMYCIN;

AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; ENTEROBACTER; ERADICATION THERAPY; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; RECURRENT DISEASE; SPECIES DIFFERENCE; TREATMENT OUTCOME;

EID: 77951588116     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.2.103     Document Type: Article

References (38)

1. Jacohs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001;7:589-596
2. Preston SL. The importance of appropriate antimicrobial dosing; pharmacokinetic and pharmacodynamic considerations. Ann Pharmacother 2004;38 (9 Suppl):S14-8.
3. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.
4. Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models. Ann Pharmacother 2003;37:1287-1298
5. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001;47:129-140
6. Garau J. Why do we need to eradicate pathogens in respiratory tract infections? Int J Infect Dis 2003;7 Suppl 1:S5-12.
7. Stratton CW. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis 2003;9:10-16
8. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-1081
9. Craig WA, Dalhoff A. Pharmacodynamics of fluoroquinolones in experimental animals. In: Kulman J. Dalhoff A. Zeiler HJ, eds. Quinolone antibacterials. Heidelberg: Springer-Verlag Berlin 1998;207-232
10. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585-590
11. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002;34:634-640
12. Senol E. Stenotrophomonas maltophilia: the significance and role as a nosocomial pathogen. J Hosp Infect 2004;57:1-7.
13. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006;43 Suppl 2:S49-56.
14. McGowan JE, Jr. Resistance in nonfermenting Gram-negative bacteria: multidrug resistance to the maximum. Am J Med 2006;119(6 Suppl 1):S29-36.
15. Fink MP, Snydman DR, Niederman MS, Leeper KV Jr, Johnson RH, Heard SO et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastin. Antimicrob Agents Chemother 1994;38:547-557
16. Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998;42:521-527
17. Beam TR, Jr., Gilbert DN, Kunin CM. General guidelines for the clinical evaluation of anti-infective drug products. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992;15 Suppl 1:S5-32.
18. Chow AW, Hall CB, Klein JO. Kammer RB, Meyer RD, Remington JS. General guidelines for the evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 Suppl 1:S62-88.
19. Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn Microbiol Infect Dis 2008;61:86-95
20. Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles, I: Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP 1991;25:1050-1057.
21. Schentag JJ, Nix DE, Forrest A, Adelman MH. AUIC: the universal parameter within the constraint of a reasonable dosing interval. Ann Pharmacother 1996;30:1029-1031.
22. Koch-Weser J, Sellers EM. Binding of drugs to serum albumin (first of two parts). N Engl J Med 1976;294:311-316.
23. Wise R. Protein binding of beta-lactams: the effects on activity and pharmacology particularly tissue penetration. I. J Antimicrob Chemother 1983;12:1-18.
24. Barriere SL. Bacterial resistance to beta-lactams, and its prevention with combination antimicrobial therapy. Pharmacotherapy 1992;12:397-402.
25. DeRyke CA, Lee SY, Kuti JL, Nicolau DP. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. Drugs 2006;66:1-14.
26. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001;33 Suppl 3:S147-56.
27. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J Infect Dis 2002;185:561-565
28. Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 2003;52:11-17
29. Jumbe N, Louie A, Leary R, Liu W, Deziel MR, Tam VH et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003;112:275-285
30. Tam VH, Louie A, Deziel MR, Liu W, Leary R, Drusano GL. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis 2005;192:420-428
31. MacGowan AP, Rogers CA, Holt HA, Bowker KE. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2003;47:1088-1095
32. Macia MD, Borrell N, Segura M, Gomez C, Perez JL, Oliver A. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:975-983
33. Drlica K, Zhao X, Blondeau JM, Hesje C. Low correlation between MIC and mutant prevention concentration. Antimicrob Agents Chemother 2006;50:403-404
34. Gugel J, Dos Santos Pereira A, Pignatari AC, Gales AC. beta-Lactam MICs correlate poorly with mutant prevention concentrations for clinical isolates of Acinetobacter spp. and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:2276-2277
35. Hansen GT, Zhao X, Drlica K, Blondeau JM. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int J Antimicrob Agents 2006;27:120-124
36. Zhanel GG. Mayer M, Laing N, Adam HJ. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:2228-2230
37. Olofsson SK, Marcusson LL, Lindgren PK, Hughes D, Cars O. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 2006;57:1116-1121
38. Olofsson SK, Marcusson LL, Stömbäck A, Hughes D, Cars O. Dose-related selection of fluoroquinolone-resistant Escherichia coli. J Antimicrob Chemother 2007;60:795-801.